MedTrace Logo

Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)

NCT05528913 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-01-08

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, Phase 2, 12-Week treatment study with a 10-Week Follow-up period to assess the efficacy and safety of Benralizumab (anti-IL5Rα) in adult patients with chronic prurigo (BICPIC)

Conditions

  • Chronic Prurigo

Interventions

DRUG

Fasenra Prefilled Syringe

Fasenra 60mg s.c. administration at weeks 0,4 and 8

OTHER

Matching Placebo Solution

Placebo s.c. administration at weeks 0,4 and 8

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Martin Metz, Prof. · Charité University, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2023-10-19
Completion
2023-10-19

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05528913 on ClinicalTrials.gov